19.06.2018
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler is Manufacturing Partner for Bayer's Innovative Targeted Thorium Conjugates in Europe
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Contract
Eckert & Ziegler is Manufacturing Partner for Bayer's Innovative Targeted
Thorium Conjugates in Europe
19.06.2018 / 14:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 19 June 2018. Eckert & Ziegler AG, a specialist for scientific,
medical, and industrial applications of radioisotopes, has been selected as
manufacturing partner for clinical supply of Bayer's innovative Targeted
Thorium Conjugates (TTCs) in Europe. TTCs are a versatile, next-generation
targeted alpha therapy (TAT). The approach uses tumor targeting molecules
such as antibodies that carry alpha-particle emitting Thorium-227 to the
tumor. TTCs have the potential to be used in a broad range of tumors, and
also for patients who are refractory to chemotherapy or conventional
targeted oncologics. Bayer has established scalable Good Manufacturing
Practices (GMP) processes for the alpha-emitter Thorium-227. Eckert &
Ziegler will provide the infrastructure for handling, manufacture and
distribution of the TTCs for the purpose of clinical trial testing in
Europe.
"We are delighted to have been selected as a partner for this interesting
and important product platform," says Dr. André Heß, Member of the Executive
Board of Eckert & Ziegler and Head of the Radiopharma Segment. "The decision
demonstrates how well our Radiopharma Segment can support the requirements
of innovative partners by the provision of exceptional radiopharmaceutical
expertise, all of which is backed-up by a world-wide logistics
infrastructure. We are excited about the potential of this innovative
platform technology as Thorium-227 can be coupled with various biomolecules
addressing different tumor types."
About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is one
of the world's largest providers of isotope technology for radiation therapy
and nuclear medicine and has around 800 employees worldwide. It globally
provides nuclear medicine institutions with synthesis technology, quality
control instruments, and pharmaceutical grade radioisotopes, among them
Yttriga(R), a precursor for Yttrium based oncology products, and
GalliaPharm(R);
a Gallium-68 radionuclide generator for diagnostic applications.
Contributing to saving lives.
Contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
---------------------------------------------------------------------------
19.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
696681 19.06.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ